Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH

Prostate

Volumn 37, Issue 4, 1998, Pages 246-252

  Denis, Louis ^a   Pagano, Francesco ^b   Nonis, Atanasio ^c   Robertson, Chris ^c   Romano, Paolo ^d   Boyle, Peter ^c  

^a Oncology Centre of Antwerp   (Belgium)

^b UNIVERSITY OF PADOVA   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d Medical Department   (Italy)

Author keywords

BPH; Estrogen withdrawal therapy; Mepartricin

Indexed keywords

MEPARTRICIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; ORGAN SIZE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME; URINE VOLUME;

AGED; DIURESIS; DOUBLE-BLIND METHOD; HUMANS; MALE; MEPARTRICIN; MIDDLE AGED; PLACEBOS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE;

EID: 0031726735     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19981201)37:4<246::AID-PROS6>3.0.CO;2-6     Document Type: Article

References (29)

1. Garraway WM, Kirby RS: Benign prostatic hyperplasia: Effects on quality of life and impact on treatment decisions. Urology 1994; 44:629-636.
2. Berry SJ, Coffey DS, Walsh PC, Ewing LL: The development of human benign prostatic hyperplasia with age. J Urol 1984;132: 474-479.
3. Jolleys JV, Donovan JL, Nanchahal K, Peters TJ, Abrams P: Urinary symptoms in the community: How bothersome are they? Br J Urol 1994;74:551-555.
4. Zumoff B, Strain GW, Kream J, O'Connor J, Rosenfeld RJ, Levin J, Fukashima DK: Age variation of the 24-hour mean plasma concentrations of androgens, estrogens and gonadotropins in normal adult men. J Clin Endocrinol Metab 1982;54:534-538.
5. Schulze H, Claus S: Histologic localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry. Prostate 1990;16:331-343.
6. Partin AW, Oesterling JE, Epstein JI, Horton R, Walsh PC: Influence of age and endocrine factors on the volume of benign prostatic hyperplasia. J Urol 1991;145:405-409.
7. Suzuki K, Ito K, Ichinge Y, Kurokawa K, Suzuki T, Imai K, Yamanaka H, Homma S: Endocrine environment of benign prostatic hyperplasia: Prostate size and volume are correlated with serum estrogen concentration. Scand J Urol Nephrol 1995; 29:65-68.
8. Gingell JC, Knonagel H, Kurth KH, Tunn UW: Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group. J Urol 1995;154:399-401.
9. Bruzzese T, Binda I, Di Nardo A, Ghielmetti G, Riva M: Partricin methyl ester, a semisynthetic polyene antibiotic. Experientia 1972;28:1515-1516.
10. Drikorn K, Borowski A, Braeckman J, Denis L, Ferrari P, Gerber G, Levin R, Lowe F, Perrin P, Senge T: Other medical therapies. In Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy G (eds): "Fourth International Consultation on Benign Prostatic Hyperplasia," Paris: S.C.I., 1997:633-659.
11. Del Vecchio S, Ulissi A, Delle Monache M, Tavanti A, Rapolli M, Ruozi P, De Bernardi M, Ricci GL: Faecal elimination of steroids in rats after oral administration of mepartricin. J Int Med Res 1990;18:468-478.
12. Shakutou S, Bandoh K, Yoshinaka Y, Kobayashi H, Yamanaka H: Effects of mepartricin, a polyene macrolide agent, on fecal excretion and serum concentration of estrogen and number of prostatic estrogen receptors in immature rats. Prostate 1998; in press.
13. Lotti T, Mirone V, Prezioso D, De Bernardi M, Rapocci MP, Ruozi P: Observations on some hormone fractions in patients with BPH treated with mepartricin. Curr Ther Res 1988;44:3402-409.
14. Griffiths K, Cockett ATK, Coffey D, Krieg M, Lee C, McKeeham W, Neal ED, Partin A, Schalken J: Regulation of prostatic growth. In Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy G (eds): "Fourth International Consultation on Benign Prostatic Hyperplasia," Paris: S.C.I., 1997:83-128.
15. Tosto A, Dattolo E, Serni S, Rizzo M, Costantini A: A doubleblind study of the effects of mepartricin in the treatment of obstruction due to benign prostatic hyperplasia. Curr Ther Res 1995;56:1270-1275.
16. Mirone V, Prezioso D, Palmieri A, Bocchini P: Validitá terapeutica della mepartricina nella IPB: Due anni di esperienza. Note preliminari sull'influenza della mepartricina su alcuni possibili fattori etiopatogenetici dell'IPB. Minerva Urol Nefrol 1998;40: 16-17.
17. McConnell J, Bartsch G, Debruyne F, Le Duc A, Mahler C, Pavone-Macaluso M, Radlmaier A, Tunn A, Stoner E: Hormonal treatment of benign prostatic hyperplasia. In Cockett ATK, Aso Y, Chatelain C, Denis L, Griffiths K, Khoury S, Murphy G (eds): "First International Consultation on Benign Prostatic Hyperplasia," Paris: S.C.I., 1991:179-191.
18. Hand DJ, Taylor CC: "Multivariate Analysis of Variance and Repeated Measures. A Practical Approach for Behavioural Scientists." London: Chapman and Hall, 1987.
19. Goldstein H: "Multilevel Statistical Models," 2nd ed. London: Edward Arnold, 1995.
20. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-539.
21. Walsh PC: Treatment of benign prostatic hyperplasia. N Engl J Med 1996;355:586-587.
22. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan DE, Pappas F, Taylor A, Binkowitz B, Jennifer NG: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-1191.
23. Finasteride Study Group: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:291-299.
24. Seppelt U: Correlation among prostate stroma, plasma estrogen levels and urinary estrogen excretion in patients with benign prostatic hypertrophy. J Clin Endocrinol Metab 1978;47:1230-1235.
25. Larsson B, Andersson KE, Batra S, Mattiasson A, Sjogren C: Effects of estradiol on norepinephrine-induced contraction, alpha adrenoceptor number and norepinephrine content in the female rabbit urethra. J Pharmacol Exp Ther 1984;229:557-563.
26. Morita T, Tsuchiya N, Tsujii T, Kondo S: Changes of autonomic receptors following castration and estrogen administration in the male rabbit urethral smooth muscle. J Exp Med 1992;166: 403-405.
27. De Bernardi M, Santucci V, Colombo L: Pharmacologic treatment of benign prostatic hyperplasia. A multicenter clinical study with mepartricin. Curr Ther Res 1988;24:1159-1172.
28. Sweeney M, Roehrborn CG, Boyle P, Bartsch G, Jardin A, Kirby R: Sexual dysfunction in European patients with benign prostatic hvperplasia (BPH). J Urol [Suppl]1997;157:1288.
29. Finkle AL, Prian DV: Sexual potency in elderly men before and after prostatectomy. JAMA 1966;196:139-143.